24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost

A Crossover, Double-Masked Comparison Investigating the 24-Hour Intraocular Pressure Control With the Travoprost/Timolol Fixed Combination Versus Travoprost, When Both Are Given in the Evening, in Subjects With Primary Open-Angle Glaucoma

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00444184

Enrollment

Registered

2007-03-07

Start date

2007-03-31

Completion date

2008-01-31

Last updated

2014-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

travoprost/timolol fixed combination

Brief summary

This 8-week, crossover study will compare the quality of 24-hour IOP control with TTFC versus travoprost when both medications are dosed in the evening. Such a crossover comparison may determine the real efficacy of the new fixed combination versus travoprost monotherapy. The results should enhance the investigators understanding on the best dosing of TTFC and may influence its clinical use in Europe. Finally, the results would better delineate the future role of TTFC in glaucoma management after PG monotherapy, or instead of unfixed therapy with PG analogs and timolol. This study should assist the general ophthalmologist worldwide to plan optimal stepwise medical therapy.

Interventions

DRUGTravoprost/timolol fixed combination, travoprost

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

29 Years to 81 Years

Healthy volunteers

Inclusion criteria

* Consecutive adults with primary open-angle glaucoma (POAG) who exhibit a mean untreated IOP greater than 23 m Hg at baseline (10:00). * Patient has POAG and is older than 29 years * The IOP without treatment is greater than 23 mm Hg and lower than 38 mm Hg at baseline (2 readings at 10:00) * Patient can be safely washed out without risk for significant deterioration * Distance best corrected Snellen visual acuity better than 1/10 * Patient can understand the instructions and comply to medications * Open normal appearing angles

Exclusion criteria

* Contraindications to prostaglandins or β-blockers * History of lack of response (\<10% reduction) to any medication * Female of childbearing potential or lactating mother * History of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses * Sign of ocular infection, except blepharitis, corneal abnormality that may affect IOP measurements etc

Design outcomes

Primary

Measure	Time frame
Mean 24-hour IOP	3 months

Secondary

Measure	Time frame
Mean reduction from baseline	3 months
Mean fluctuation of 24-hour IOP	3 months
Individual IOP readings measured at 10:00 (± 1 hour) and at +4, +8, +12, +16 and +20 (± 1 hour) hours.	3 months

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026